Page 32 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Benzodiazepine use and retention in OAT

Methodology and Location Retrospective cohort study of patients in methadone maintenance treatment in Vancouver, Canada. Retrospective chart review of patients in methadone maintenance treatment in Toronto, Canada. Sequential-admission retrospective study in buprenorphine treatment programs in Boston, USA Retrospective chart review on patients in methadone maintenance treatment in Washington, DC, USA Retrospective cohort

Psychiatric Comorbidity Depression 42 – 68% Anxiety 18 – 52% Excluded Ss with DSM Axis 1 disorder Dx of mood/anxiety disorder 36-81%

ND ND ND ND ND

Polysubstance use Amphetamine 47% Cocaine 90% Alcohol 60 – 84% Cannabis 52 – 68% Cocaine 48 – 63% Cocaine 10 – 25% Cannabis 22 – 33% Amphetamine 4 – 8% Cocaine 29% Cannabis 27% Amphetamine 43% ND Alcohol 21% Cannabis 26% ND ND

Community health center Outpatient hospital clinic Academic community healthcare system Private, non-profit MMT clinic Tertiary care drug dependence treatment center 58 addiction treatment centers 52 addiction treatment centers

Setting addiction treatment center

MOUD dose (±SD) Methadone 88.5 (56.8) mg/day ND ND ND ND ND Methadone 75 – 85 (33 – 36) mg/day Suboxone 8 – 12 (7 – 8) mg/day Methadone 64 (30) – 69 (31) mg/day

Sex (%) 35% M; 65% F 26 – 48% F 35 – 64% F 61% M ND 99% M 56 – 60% M: 40 – 44% F 50 – 57% M: 43 – 50% F

Age (±SD) 39.2 (6.4) 31.9 (1.1) – 38.2 (1.2) 35.6 (10.5) – 37.7 (11.6) 53 (range 20 – 79) ND 30.4 (10.1) 30.8 (10.2) – 34.3 (10.9) 31.3 (9.7) – 37.5 (10.8)

Table 3. Study characteristics Number of Subjects 60 Raffa et al. 47 172 Brands et al. 40 386 Schuman-Olivier 604 White et al. 48 787 Peles et al. 50 140 Dayal et al. 43 3850 Franklyn et al. 42 3692 Eibl et al. 49

Study

Volume 8 Issue 3 (2025) et al. 45 26 doi: 10.36922/itps.5151